Can early UVB and steroids stop vitiligo in its tracks?
NCT ID NCT04843059
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested whether starting treatment early with UVB light therapy and low-dose steroids can stop vitiligo from spreading and improve skin color return. 51 people with different stages of vitiligo were treated for 6 months. Researchers took skin samples to see how immune cells changed. The goal is to find a way to prevent relapses, which happen in up to half of patients after repigmentation.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- narrowband UVB light therapy and oral steroids (methylprednisolone)
- What this could lead to
- If successful, this approach could lead to better repigmentation and fewer relapses for people with vitiligo by targeting the immune cells in the skin early.
- What could go wrong
- This is a small, early-stage study (51 people) without a placebo group, so results may not apply to everyone. Steroids and UVB have side effects, and long-term benefits are uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
51 people
The number who actually took part.
- Started
-
Jun 2021
- Finished
-
Aug 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 35 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 1\. Patients with non-segmental vitiligo. 3 groups of patients will be selected: * Patients with a long-lasting disease (more than 2 years) and no new or growing lesion since at least 2 years * Patients with a long-lasting disease (more than 2 years) and with at least one new lesion since less than 6 months * Patients developing for the first-time vitiligo lesions with all the lesions no older than 6 months 2. ≥ 18 and \<35 years to have a homogeneous distribution of age between the three groups, as 80% of vitiligo cases start before the age of 30. 3\. Patient with at least one lesion of more than 2 cm² not located on the face, hands or feet. 4\. Patient needing a treatment with oral minipulses of steroids and phototherapy 5. For women of child-bearing age, an effective contraception (estroprogestative pill, contraceptive implant, IUD, condoms or tubal ligation) should be used for more than one month before the inclusion in the study. A urine pregnancy test (βHCG in urines) will be performed. 6\. Affiliation to a social security system 7. Signed informed consent Exclusion Criteria: * 1\. Pregnant or breast-feeding women. Or women who plan to get pregnant during the study duration. 2\. Segmental or mixed vitiligo 3. Vitiligo located only on face, hands and feet 4. Exposure to solar or artificial UV during the months before inclusion 5. Concomitant use of topical or systemic immunosuppressive medication or steroids 6. Patients suffering from photodermatosis or taking photosensitive drugs 7. Personal history of skin cancer. 8. Patients with diabetes, high blood pressure, osteoporosis or any other contra-indication to the use of systemic steroids. 9\. Vulnerable people: pregnant or breast-feeding women, minors, adult under guardianship or deprived of freedom 10. Participants in other clinical therapeutic studies involving a drug that could interfere with the present evaluation
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Vitiligo are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Bordeaux
Bordeaux, 33440, France
-
CHU de Nice
Nice, alpes maritimes, 06001, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a skin cream bring back color to faces with vitiligo?
- Skin markers may reveal how light therapy fights vitiligo
- Can Real-World data unlock better skin disease care?
- New ointment aims to restore skin color in vitiligo
- Skin microbes linked to vitiligo and immunotherapy reactions in melanoma patients
- New vitiligo registry aims to uncover disease trends in 2,500 patients